Based in Cambridge, UK, we’re working with partners to provide novel solutions in drug and vaccine development. Using our unique technology, we rapidly develop broad diversity, high quality human antibodies against challenging targets.
With investment totalling $220m, we are using our Kymouse™ platform to help our partners to realise new opportunities in therapeutic and vaccine development.
From the Wellcome Trust Sanger Institute’s first spin-out to a leading therapeutic antibody company.Learn more
Our vision is to be a global biopharmaceutical company, driving the development of therapeutic human antibodies.Learn more
We work in partnerships, enhancing each other’s complementary skills to rapidly discover and test validated lead prospects.Learn more
Led by a team with world-class antibody development experience, we recruit key people to all parts of Kymab with a proven record in drug development, antibody therapeutics, disease studies, business development and financial control.
Kymab Group Ltd: The Bennet Building (B930), Babraham Research Campus, Cambridge, United Kingdom, CB22 3AT. Registered in England. Company registration number 10414057.
Kymab has one of the most comprehensive transgenic technologies.